Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsNucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivativesPrevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovirAn analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitorsPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionPharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionPre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen.Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.AIDS vaccines and preexposure prophylaxis: is synergy possible?Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.HIV prevention by oral preexposure prophylaxis.Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)An update and review of antiretroviral therapy.Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.Review of tenofovir-emtricitabine.Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs.Systemic preexposure prophylaxis for human immunodeficiency virus infection.Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature.Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells.Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent.Is stavudine triphosphate a natural metabolite of zidovudine?Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.Interlaboratory measurement differences in intracellular carbovir triphosphate concentrations in HIV-infected patients: sources of variability in processing, shipping, and quantitation.
P2860
Q24674939-42262749-78FA-41C7-920E-72F46CCB159FQ27660045-C85B95F8-D49A-4A45-8EC7-32BB780C6604Q28472146-6AF6B935-C9B5-4ECC-A243-A1695C278795Q28474361-BDAA6969-8A0C-4F4B-8BFE-2C02FC3B645CQ28481276-29D20010-9D12-44FA-A6F1-A619130C1566Q34057568-994F4526-5082-4FF7-BAEF-5146EDAA29A9Q34481359-7F1644D3-F0CB-4F07-95B1-A6AEAF79264BQ34483566-14AA84AE-04D0-49E9-A48B-A2FC7935B702Q34506545-0E52F137-A50C-45BC-BC88-15995630265DQ34737466-BD459822-67CC-40F4-94C9-C95CE530523CQ35003539-A6425466-BDC1-483F-A59A-63C44A1617B5Q35005051-B405B1EF-19AB-446E-84D9-D01F7E93E018Q35077568-559CF36B-1A42-479B-B6FA-6493FFB87AB4Q35363649-E9514303-D44D-4A2C-AB23-5B0928C52882Q35666402-3703B9AD-470F-45D9-A7BA-D2A122AC3C2BQ35765743-4040F2A8-B239-4DAE-8911-8BD663CA6295Q36172455-361AC45E-45CC-413D-B6F3-1058398442FDQ36188725-17E43C0A-BADA-48B7-BE33-700BFA554624Q36364164-3DD78819-3CF1-49B5-AB41-0A7E086EECF9Q36406923-BF87DF40-46D6-4AFD-A1C8-4E9BF5EBF6F9Q36545072-FC2FB99D-E740-4C8E-8FF0-AB3BE5BA8CCEQ36554980-A87ACFF0-D157-4BC8-A4A5-CA2E222615ADQ36663686-6192CD89-AA68-4799-AC29-3DB3C799B345Q36723853-688B6429-26CF-4E5F-980C-0B9D0DC83DFFQ36870864-43478114-FC16-496E-86EC-74643AE21486Q37190767-B3DF8F44-16C9-40B6-8210-D7BE87F257A5Q37258298-E68F53BA-378C-4A3A-99CD-4A501D387065Q37421891-E804A0B5-913D-4AA5-B831-CA6016838CECQ37771921-2044B60F-D7B4-4609-B905-E9260487F2ECQ37793090-75E4127E-752B-47FB-9BE0-58E3833DA5E6Q37874616-8896519F-239A-46E7-9826-A6F9337D7543Q38040137-6B37074C-8FC1-4098-9649-9703FD48727FQ39434360-388A4116-A1C7-4A6D-BA92-C6CAF8FA2775Q39488594-202EEC86-986E-4AD3-AEDF-5DC951326463Q40324306-888F7E27-F004-47CB-BBB0-B8D5FB3E7CD3Q41915160-0743DD76-14F2-44B4-B1E8-0226E3ECDBE6Q42549372-AB4769A3-CCC1-4DCC-9518-A3D3C3B81F07Q42747686-AC87E4B2-C810-4433-811F-80890F8AEE85Q43108142-B95FCE1D-E42A-46AD-95DC-728C7AC53836Q43447907-CC477521-FFD9-4502-BCCC-AB4D8003A176
P2860
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Measurement of intracellular d ...... ciency virus-infected patients
@ast
Measurement of intracellular d ...... ciency virus-infected patients
@en
type
label
Measurement of intracellular d ...... ciency virus-infected patients
@ast
Measurement of intracellular d ...... ciency virus-infected patients
@en
prefLabel
Measurement of intracellular d ...... ciency virus-infected patients
@ast
Measurement of intracellular d ...... ciency virus-infected patients
@en
P2093
P2860
P50
P1476
Measurement of intracellular d ...... ciency virus-infected patients
@en
P2093
Bonaventura Clotet
Elisabet García
Eulàlia Grau
Frédéric Theodoro
Henri Benech
Jacques Grassi
Jordi Puig
P2860
P304
P356
10.1128/AAC.49.5.1907-1914.2005
P407
P577
2005-05-01T00:00:00Z